VIDEO: AbbVie presents emerging data on Rinvoq, Skyrizi clinical trials

VIDEO: AbbVie presents emerging data on Rinvoq, Skyrizi clinical trials

In a video exclusive, Remo Panaccione, MD, University of Calgary, outlined new therapeutic data for the treatment of patients with inflammatory bowel diseases at the 16th Congress of European Crohn’s and Colitis Organisation.Highlighted studies included the U-ACHIEVE and U-ACCOMPLISH phase 3 therapeutic induction studies in which researchers evaluated the safety and efficacy of Rinvoq (upadacitinib) for the treatment of patients with moderate to severe ulcerative colitis. Primary reported endpoints were clinical, endoscopic and histologic outcomes after 8-weeks of treatment.PanaccioneRead More

Share on facebook
Share on twitter
Share on linkedin